The APIs listed below are the main Anti-Cancer / Oncology ingredients that are presently available from LGM Pharma:
- Afatinib Dimaleate
- Aflibercept
- Anastrozole
- Axitinib
- Azacitidine
- Besifloxacin Hydrochloride
- Bexarotene
- Bicalutamide
- Bortezomib
- Bosutinib
- Cabozantinib Malate
- Capecitabine
- Carfilzomib
- Carmustine
- Ceritinib
- Clofarabine
- Crizotinib
- Dabrafenib Mesylate
- Dactinomycin
- Dasatinib
- Doxorubicin Hydrochloride
- Enzalutamide
- Erlotinib Hydrochloride
- Fulvestrant
- Gefitinib
- Ibrutinib
- Idarubicin Hydrochloride
- Imatinib Mesylate
- Ixabepilone
- Lapatinib Ditosylate
- Lenalidomide
- Nelarabine
- Nilotinib Hydrochloride
- Pazopanib Hydrochloride
- Pemetrexed Disodium
- Ponatinib Hydrochloride
- Regorafenib
- Romidepsin
- Ruxolitinib Phosphate
- Sorafenib Tosylate
- Sunitinib Malate
- Temozolomide
- Vandetanib
- Vandetinib
- Vatalanib Succinate
- Vemurafenib
- Vismodegib
We constantly aim to provide top technical support and full regulatory documentation (TDP / CTD / E-DMF / CEP / US-DMF etc…) even for the most recently approved APIs, originating from EU-GMP certified and US-FDA approved production facilities. Many of the above APIs are manufactured via non-infringing routes of synthesis and would be suitable for Paragraph IV challenges / early launch in regulated markets.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1).
Any patent infringement and resulting liability is solely at buyer risk.
